Anti-adalimumab antibodies mean poorer outcomes in psoriatic arthritis

Psoriatic arthritis patients with detectable anti-adalimumab antibodies have significantly lower serum adalimumab concentrations and poorer clinical outcomes at 28 weeks and 52 weeks of treatment,...